> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Reg Review Period for Endorecherche’s Intrarosa
- URL: https://www.fdaweb.com/reg-review-period-for-endorecherches-intrarosa/
- Published: 2020-02-18T12:00:00.000Z
- Updated: 2026-09-14T16:03:28.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5146105

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Endorecherche’s Intrarosa (prasterone), indicated for treating moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. The regulatory review period is 3,381 days, which includes 2,983 days that occurred during the testing phase and 398 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2020-02-18/pdf/2020-03115.pdf?ref=fdaweb.com).